Dorda, working with Loyens & Loeff, has advised Croma-Pharma on entering into a business combination agreement with the European Healthcare Acquisition & Growth Company. Schoenherr, working with Sullivan & Cromwell and Houthoff, advised EHC.
The transaction remains contingent on regulatory approval.
Croma-Pharma is an Austria-based family-owned company operating in the fields of minimally invasive aesthetics and reconstructive medicine. With 550 employees, 13 subsidiaries in Europe and Brazil, two joint ventures, and 60 exclusive export partners, it distributes its products in 80 markets worldwide and operates as a contract manufacturer in ophthalmology and orthopedics.
The European Healthcare Acquisition & Growth Company is a Dutch special-purpose acquisition company listed on Euronext Amsterdam.
According to Dorda, “through this transaction, Croma will be indirectly listed on Euronext Amsterdam and thus gain access to the capital market, which is important for the financing of the further growth course.”
Dorda’s team included Partners Juergen Kittel and Christoph Brogyanyi, Attorney Clemens Burian, and Associates Philipp Partan and Isabel Maurer.
Schoenherr's team included Partner Sascha Hoedl, Attorney Joseph Moser, and Associate Gabor Kulcsar.
